Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-27
DOI
10.1038/s41416-020-0994-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) O Michielin et al. ANNALS OF ONCOLOGY
- 1365PFinal results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment
- (2019) K Yokota et al. ANNALS OF ONCOLOGY
- LBA70Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial
- (2019) J A Chesney et al. ANNALS OF ONCOLOGY
- Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study.
- (2018) Igor Samoylenko et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716).
- (2018) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).
- (2018) Robert Hans Ingemar Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
- (2018) Antoni Ribas et al. Cancer Discovery
- LBA45Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- 1267PTopline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy
- (2018) T Isei et al. ANNALS OF ONCOLOGY
- Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
- (2018) A Marabelle et al. ANNALS OF ONCOLOGY
- 1245PDIntratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study
- (2018) A Diab et al. ANNALS OF ONCOLOGY
- 1265PPhase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
- (2018) A Ribas et al. ANNALS OF ONCOLOGY
- 1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study
- (2018) H Gogas et al. ANNALS OF ONCOLOGY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)
- (2017) David A Canton et al. Immunotherapy
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A practical guide to the handling and administration of talimogene laherparepvec in Europe
- (2017) Kevin Harrington et al. OncoTargets and Therapy
- Current status and perspectives in immunotherapy for metastatic melanoma
- (2017) Riccardo Marconcini et al. Oncotarget
- Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
- (2017) Melissa Bedard et al. Frontiers in Immunology
- Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
- (2017) Ibrahim Ragab Eissa et al. Frontiers in Oncology
- The MITCI (phase 1b) study: a novel immunotherapy combination of coxsackievirus A21 and ipilimumab in patients with advanced melanoma
- (2016) B. Curti et al. ANNALS OF ONCOLOGY
- Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma
- (2016) R. Andtbacka et al. ANNALS OF ONCOLOGY
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study
- (2016) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
- (2016) Christoph Hoeller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally
- (2016) M. Angela Aznar et al. JOURNAL OF IMMUNOLOGY
- The immune system and cancer evasion strategies: therapeutic concepts
- (2016) S. Muenst et al. JOURNAL OF INTERNAL MEDICINE
- Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
- (2016) Kevin Harrington et al. OncoTargets and Therapy
- A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
- (2016) Abhijit Ray et al. Oncotarget
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
- (2016) Hasan Rehman et al. Journal for ImmunoTherapy of Cancer
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
- (2015) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma
- (2015) G.V. Long et al. EUROPEAN JOURNAL OF CANCER
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
- (2015) Robert HI Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
- (2014) John F. Thompson et al. ANNALS OF SURGICAL ONCOLOGY
- Treatment of in-transit melanoma with intra-lesional interleukin-2: A systematic review
- (2014) Brett A. Byers et al. JOURNAL OF SURGICAL ONCOLOGY
- Intra-lesional interleukin-2 therapy for in transit melanoma
- (2014) Claire F. Temple-Oberle et al. JOURNAL OF SURGICAL ONCOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Locoregional Therapies in Melanoma
- (2014) Andrea M. Abbott et al. SURGICAL CLINICS OF NORTH AMERICA
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
- (2014) B. Weide et al. Cancer Immunology Research
- Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
- (2014) Howard L Kaufman et al. Journal for ImmunoTherapy of Cancer
- Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
- (2013) M. Nishino et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
- (2013) Paul Toomey et al. PLoS One
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- High response rate after intratumoral treatment with interleukin-2
- (2010) Benjamin Weide et al. CANCER
- Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up
- (2010) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pattern Recognition Receptors and Inflammation
- (2010) Osamu Takeuchi et al. CELL
- Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
- (2009) G Alì et al. BRITISH JOURNAL OF CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started